We are live on ! Find out more
BEAM icon

Beam Therapeutics
BEAM

214 hedge funds and large institutions have $1.82B invested in Beam Therapeutics in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $16.6M | Put options by funds: $7.11M

18% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 62

8.14% more ownership

Funds ownership: 86.14% → 94.28% (+8.1%)

3% less funds holding

Funds holding: 221 → 214 (-7)

12% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 41

22% less capital invested

Capital invested by funds: $2.32B → $1.82B (-$504M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
214
Holders Change
-7
Holders Change %
-3.17%
% of All Funds
3.09%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
36
Increased
73
Reduced
62
Closed
41
Calls
$16.6M
Puts
$7.11M
Net Calls
+$9.45M
Net Calls Change
+$24.8M

Top Buyers

1
AVM
Arch Venture Management
Illinois
+$134M
2
FCM
Farallon Capital Management
California
+$83.5M
3
First Trust Advisors
First Trust Advisors
Illinois
+$36.4M
4
BlackRock
BlackRock
New York
+$22.8M
5
Deutsche Bank
Deutsche Bank
Germany
+$19.7M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$81.5M
2
DGM
Darwin Global Management
Jersey
-$70M
3
AIM
ARK Investment Management
Florida
-$13.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$12M
5
Pictet Asset Management
Pictet Asset Management
Switzerland
-$7.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
$185M +$83.5M +3,401,370 +75%
Vanguard Group
2
Vanguard Group
Pennsylvania
$185M +$7.9M +321,611 +4%
BlackRock
3
BlackRock
New York
$179M +$22.8M +928,753 +14%
AIM
4
ARK Investment Management
Florida
$179M -$13.7M -556,035 -7%
AVM
5
Arch Venture Management
Illinois
$128M +$134M +5,443,039 New
Fidelity Investments
6
Fidelity Investments
Massachusetts
$103M -$12M -486,758 -10%
State Street
7
State Street
Massachusetts
$81.8M -$5.87M -239,037 -6%
MM
8
MWG Management
British Virgin Islands
$53.1M -$1.96M -80,000 -3%
Sumitomo Mitsui Trust Group
9
Sumitomo Mitsui Trust Group
Japan
$52.1M -$3.37M -137,402 -6%
NAMA
10
Nikko Asset Management Americas
New York
$52.1M -$3.37M -137,402 -6%
Temasek Holdings
11
Temasek Holdings
Singapore
$42.5M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$40.5M +$2.28M +92,859 +6%
RG
13
Redmile Group
California
$39.9M -$4.34M -176,556 -9%
First Trust Advisors
14
First Trust Advisors
Illinois
$34.7M +$36.4M +1,482,271 New
BG
15
Bellevue Group
Switzerland
$33.2M +$5.53M +225,000 +19%
T. Rowe Price Associates
16
T. Rowe Price Associates
Maryland
$32.7M +$3.62M +147,484 +12%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$24.6M +$10M +407,499 +63%
Deutsche Bank
18
Deutsche Bank
Germany
$20.2M +$19.7M +801,238 +1,319%
YCM
19
Yiheng Capital Management
California
$19.8M – – –
Morgan Stanley
20
Morgan Stanley
New York
$18.8M -$81.5M -3,319,746 -81%
Goldman Sachs
21
Goldman Sachs
New York
$18.4M +$5.71M +232,351 +42%
Citadel Advisors
22
Citadel Advisors
Florida
$18M +$17.9M +729,641 +1,847%
JP Morgan Chase
23
JP Morgan Chase
New York
$16.2M +$5.52M +224,579 +48%
CC
24
Casdin Capital
New York
$15.8M – – –
Northern Trust
25
Northern Trust
Illinois
$15.4M -$44.2K -1,798 -0.3%
1
2 3 4 5

BEAM Hedge Fund Activity: Q2 2024 in Review

214 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2024, worth a combined $1.82B — down 22% from $2.32B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of BEAM and 36 opened new positions — a net loss of 5 holders — while 62 trimmed existing stakes and 73 added.

The largest buyer was Arch Venture Management, opening a new position worth an estimated $134M. The largest seller was Morgan Stanley, cutting an estimated $81.5M.

  • 214 institutional investors held Beam Therapeutics (BEAM) as of Q2 2024, down from 221 in Q1 2024.
  • Funds reported $1.82B of Beam Therapeutics stock for Q2 2024, down 22% quarter-over-quarter.
  • 36 funds opened new Beam Therapeutics positions in Q2 2024 and 41 closed out, a net change of -5 holders.
  • The largest Beam Therapeutics buyer in Q2 2024 was Arch Venture Management, an estimated $134M added.
  • The largest Beam Therapeutics seller in Q2 2024 was Morgan Stanley, an estimated $81.5M sold.

Based on aggregated 13F filings for Q2 2024.